Original Publication Date: 14 March, 2014
Publication / Source: Future Oncology
Authors: Carlo Buonerba & Giuseppe Di Lorenzo
An unprecedented large number of agents capable of prolonging survival is presently available for patients with castration-resistant prostate cancer (CRPC) [1,2]. Survival expectancy of a patient with newly diagnosed CRPC has approximately doubled since the approval of docetaxel, although it still appears to be poor in selected populations [3,4], such as those with primary refractoriness to docetaxel . US FDA- and EMA-approved agents now include immunotherapy agent sipuleucel-T, CYP17A inhibitor abiraterone, antiandrogen receptor enzalutamide, cytotoxic agent cabazitaxel and radiopharmeceutical agent radium-223. These agents were approved in different settings.